Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of galantamine for treatment of neuropsychiatric behaviour associated with alzheimer's disease

A technology for Alzheimer's and neuropsychiatric diseases, applied to neuropsychiatric behavioral drugs, to treat neuropsychiatric behaviors related to Alzheimer's disease, and can solve problems such as galantamine that has not been confirmed by research

Inactive Publication Date: 2003-07-16
JANSSEN PHARMA NV
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, no studies have demonstrated the use of galantamine for the treatment of neuropsychiatric behaviors associated with Alzheimer's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of galantamine for treatment of neuropsychiatric behaviour associated with alzheimer's disease
  • Use of galantamine for treatment of neuropsychiatric behaviour associated with alzheimer's disease
  • Use of galantamine for treatment of neuropsychiatric behaviour associated with alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0033] Patients (approximately 910) diagnosed with Alzheimer's disease were randomly divided into 4 treatment groups: placebo; gradually increased dose to galantamine 24 mg / day over 8 weeks; gradually increased dose to Galantamine 16mg / day; or galantamine 8mg / day, the dose is no longer gradually increased, and a total of 5 months of treatment. Patients enrolled in the study must have been diagnosed with Alzheimer's disease, Alzheimer's disease assessment grade (Rosen, W.G. et al., Amer.J.Psychiatry, 141:1356-1364, 1984) cognition Score on section (ADAS-cog-11) of at least 18 and a history of cognitive decline that was progressive at the beginning and developed over a period of at least 6 months.

[0034] The dose escalation scheme for each treatment group was as follows:

[0035] Subjects in the placebo group received placebo treatment for 21 weeks (5 months). The subjects in the Gal24 group received 4 weeks of 8mg / day galantamine (4mg, twice a day (bid)), 4 weeks of 16mg / da...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Galantamine has been used in the treatment of a number of chronic diseases. Galantamine has been found to be safe and effective in the treatment of Alzheimer's disease. Neuropsychiatric disorders are often associated with Alzheimer's disease. It is demonstrated that galantamine is also effective in reducing or stabilizing the incidence of neuropsychiatric behaviour seen in Alzheimer's patients.

Description

[0001] The present invention relates to the use of an effective amount of galantamine for the manufacture of a medicament for the treatment of neuropsychiatric behavior associated with Alzheimer's disease. Background of the invention [0002] Galantamine is a reversible cholinesterase inhibitor that can be isolated from a range of different plant sources, including the bulbs of daffodils. Galantamine can competitively interact with the enzyme, acetylcholinesterase, and shows 10 to 50 times greater selectivity for acetylcholinesterase than butyrylcholinesterase. [0003] Galantamine has been used to treat a variety of chronic conditions that require life-long treatment. Galantamine has been shown to be effective in the treatment of: Arthritis (Canadian Patent Application 2,251,114); Fatigue Syndrome (Canadian Patent Application 2,108,880); Mania (Canadian Patent Application 2,062,094); Schizophrenia (Canadian Patent Application 2,108,880) memory dysfunction, including Alzheime...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D491/08A61K31/55A61K36/18A61P25/28
CPCA61K31/55A61P25/18A61P25/28
Inventor W·L·J·帕里斯M·彭特科尔沃
Owner JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com